BioPharma Dive1h
Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer
The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...
Rocket Pharmaceuticals appoints new board member
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a biotechnology firm specializing in pharmaceutical preparations with a market capitalization of $1.12 billion, announced a recent change to its Board of ...
Vertex is hoping for 'historic' non-opioid painkiller approval. It might not be a straightforward blockbuster.
This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Vertex Pharmaceuticals' SWOT analysis: strong CF franchise fuels pipeline stock growth
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...